Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 3
2007 4
2008 20
2009 47
2010 56
2011 46
2012 35
2013 32
2014 32
2015 24
2016 21
2017 27
2018 10
2019 3
2020 4
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Results by year

Filters applied: . Clear all
Page 1
Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Int J Cancer. 2023 Nov 1;153(9):1623-1634. doi: 10.1002/ijc.34663. Epub 2023 Aug 4. Int J Cancer. 2023. PMID: 37539667
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E. Nader-Marta G, et al. Br J Cancer. 2022 Nov;127(10):1799-1807. doi: 10.1038/s41416-022-01963-8. Epub 2022 Sep 1. Br J Cancer. 2022. PMID: 36050448 Free PMC article. Clinical Trial.
Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
Park HA, Edelmann D, Canzian F, Harrison TA, Hua X, Shi Q, Silverman A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2087-2091. doi: 10.1158/1055-9965.EPI-22-0320. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35984985 Free PMC article. Clinical Trial.
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M. Agostinetto E, et al. NPJ Breast Cancer. 2022 Jul 20;8(1):87. doi: 10.1038/s41523-022-00452-8. NPJ Breast Cancer. 2022. PMID: 35859079 Free PMC article.
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart MJ, de Azambuja E. Lambertini M, et al. ESMO Open. 2020 Nov;5(6):e000979. doi: 10.1136/esmoopen-2020-000979. ESMO Open. 2020. PMID: 33154022 Free PMC article. Clinical Trial.
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Zaanan A, et al. JCO Precis Oncol. 2020 Feb 26;4:PO.19.00237. doi: 10.1200/PO.19.00237. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923882 Free PMC article.
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Leon-Ferre RA, Perez EA, Hillman DW, Bueno C, Perez AT, Chen B, Jenkins RB, Northfelt DW, Johnson DB, Carolla RL, Zon RT, Moreno-Aspitia A. Leon-Ferre RA, et al. Breast Cancer Res Treat. 2020 Aug;182(3):613-622. doi: 10.1007/s10549-020-05709-z. Epub 2020 Jun 5. Breast Cancer Res Treat. 2020. PMID: 32504284 Free PMC article. Clinical Trial.
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. Sharma MR, et al. J Clin Pharmacol. 2020 Apr;60(4):444-452. doi: 10.1002/jcph.1559. Epub 2019 Dec 4. J Clin Pharmacol. 2020. PMID: 31802506 Free PMC article.
317 results